Search results
Showing 76 to 90 of 132 results for hepatitis
Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)
Evidence-based recommendations on rituximab for untreated chronic lymphocytic leukaemia in adults.
This quality standard covers diagnosing and managing drug allergy in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS97Show all sections
Sections for QS97
- Quality statements
- Quality statement 1: Documentation using the structured assessment guide
- Quality statement 2: Advice about carrying personal structured drug information
- Quality statement 3: Referral to specialist drug allergy services
- Quality statement 4: Recording drug allergy status in electronic medical records
- Quality statement 5: Updating information on drug allergy status
- Quality statement 6 (developmental): Prescription information on drug avoidance
- About this quality standard
MRI-based technologies for assessing non-alcoholic fatty liver disease (HTG655)
Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease.
Read the biographies for all members of the NICE antimicrobial evaluation committee.
Read the biographies for all members of the NICE antimicrobial evaluation committee.
Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis in adults.
Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin (Copegus) for treating chronic hepatitis C in children and young people.
FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care (HTG682)
Evidence-based recommendations on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care.
Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making
The guidance has been withdrawn because Janssen withdrew their marketing authorisation on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.
This guideline sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations are for adults, young people and children aged 72 hours and over. They do not cover diagnosis.
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
This guidance has been withdrawn because Bristol-Myers Squibb has discontinued daclatasvir (Daklinza).
Discontinued Reference number: GID-MT117